

Appendix: Tables

1.	Sales January to June 2025 and 2024.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2025 vs. YTD June 2024	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2025	11
10.	Roche Group core results reconciliation – Half Year 2025	12
11.	Divisional core results reconciliation – Half Year 2025	13
12.	Roche Group consolidated balance sheet.....	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to June 2025 and 2024

CHF millions	Six months ended 30 June		% change	
	2025	2024	At CER	In CHF
Pharmaceuticals Division	23,985	22,637	10	6
United States	12,670	11,882	10	7
Europe	4,566	4,425	5	3
Japan	1,425	1,366	5	4
International	5,324	4,964	14	7
Diagnostics Division	6,959	7,211	0	-3
Roche Group	30,944	29,848	7	4

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024

CHF millions	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024
Pharmaceuticals Div.	11,716	9	11,620	10	11,914	12	11,949	8	12,036	11
United States	6,190	6	6,284	9	6,608	15	6,224	6	6,446	13
Europe	2,225	10	2,188	2	2,219	10	2,320	5	2,246	5
Japan	717	-3	717	1	791	1	671	3	754	7
International	2,584	23	2,431	22	2,296	11	2,734	18	2,590	11
Diagnostics Division	3,733	8	3,516	6	3,597	-1	3,491	0	3,468	0
Roche Group	15,449	9	15,136	9	15,511	9	15,440	6	15,504	8

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2025 vs. YTD June 2024

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,506	8	2,462	5	706	12	-	-	338	19
Hemlibra	2,421	17	1,324	11	493	7	183	8	421	66
Vabysmo	2,067	18	1,450	9	378	33	70	31	169	118
Tecentriq	1,733	-1	819	-6	434	3	174	-4	306	13
Perjeta	1,613	-12	677	1	282	-16	37	-44	617	-18
Xolair	1,445	34	1,445	34	-	-	-	-	-	-
Actemra/RoActemra	1,279	4	619	7	308	-14	152	5	200	26
Phesgo	1,197	55	348	39	401	15	90	80	358	182
Kadcyla	1,037	9	396	7	266	-6	45	-2	330	28
Evrysdi	869	7	309	12	292	4	46	5	222	5
Alecensa	802	8	276	20	133	-7	100	5	293	7
Polivy	730	46	327	32	160	90	99	8	144	88
MabThera/Rituxan	630	-8	387	-6	70	-8	7	-14	166	-11
Herceptin	560	-21	121	-10	150	-1	4	-51	285	-32
Activase/TNKase	550	-4	527	-3	-	-	-	-	23	-25
Avastin	522	-17	156	-20	26	-40	76	-25	264	-9
Gazyva	490	14	253	20	121	1	17	20	99	14
Pulmozyme	239	11	167	22	34	-12	-	-18	38	-3
CellCept	196	2	9	-17	65	12	24	35	98	-6
Madopar	193	1	-	-	46	-5	-	-	147	4
Xofluza	187	185	17	340	2	*	-	-	168	172
Enspryng	177	27	46	16	19	40	78	15	34	80
Columvi	123	88	78	103	25	79	-	-	20	53

Elevidys	117	316	-	-	-	-	-	-	117	316
Rozlytrek	78	29	26	12	11	9	3	-12	38	62
Lunsumio	48	33	30	9	11	39	6	-	1	*
Luxturna	36	292	36	292	-	-	-	-	-	-
Itovebi	36	-	34	-	-	-	-	-	2	-
Cotellic	24	25	12	50	5	-2	-	-	7	17
PiaSky	21	*	-	-	3	-	17	*	1	-
Susvimo	4	335	4	335	-	-	-	-	-	-
Ronapreve	-	-100	-	-	-	-100	-	-	-	-100
Pharma other	1,055	-3	315	4	125	-9	197	2	418	-8
Pharma total sales	23,985	10	12,670	10	4,566	5	1,425	5	5,324	14

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024
Ocrevus	1,701	9	1,697	11	1,688	7	1,778	6	1,728	10
Hemlibra	1,103	6	1,137	14	1,223	21	1,165	11	1,256	22
Vabysmo	947	81	1,022	59	1,048	43	1,018	18	1,049	19
Tecentriq	933	2	905	0	937	-1	870	0	863	-1
Perjeta	985	-1	888	2	807	9	840	-10	773	-14
Xolair	614	11	627	12	733	29	645	26	800	41
Actemra/RoActemra	658	8	672	7	697	4	619	-1	660	8
Phesgo	411	52	445	55	496	72	593	52	604	57
Kadcyla	516	9	495	7	504	9	506	5	531	12
Evrysdi	482	42	408	13	385	10	420	18	449	-1
Alecensa	411	10	385	7	397	8	397	11	405	6
Polivy	263	34	304	24	304	34	358	42	372	51
MabThera/Rituxan	355	-15	317	-14	356	-2	298	-16	332	1
Herceptin	376	-4	323	-13	318	-10	292	-20	268	-23
Activase/TNKase	297	-7	302	9	307	15	297	-2	253	-7
Avastin	330	-18	289	-19	290	-17	274	-15	248	-19
Gazyva	232	15	225	8	240	25	249	15	241	12
Pulmozyme	113	2	104	4	126	18	123	10	116	13
CellCept	103	9	86	-5	116	23	98	4	98	1
Madopar	109	14	78	-9	90	15	92	2	101	1

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

[illegible]

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024
Ocrevus	329	15	322	11	345	21	344	11	362	14
Hemlibra	237	12	222	3	236	15	247	7	246	7
Vabysmo	149	153	167	104	168	88	197	42	181	25
Tecentriq	219	8	220	-3	214	0	220	5	214	1
Perjeta	170	-12	161	-19	144	-9	144	-16	138	-15
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	175	-8	145	-26	150	-21	152	-19	156	-7
Phesgo	185	47	189	33	195	32	199	18	202	13
Kadcyla	143	0	140	-5	136	5	135	-7	131	-5
Evrysdi	149	16	149	13	137	3	145	6	147	3
Alecensa	73	-1	72	0	67	-5	68	-6	65	-7
Polivy	32	-23	56	2	50	38	94	74	66	119
MabThera/Rituxan	38	-14	32	-29	41	6	35	-10	35	-6
Herceptin	77	-12	73	-16	76	-6	77	0	73	-2
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Avastin	23	-14	19	-9	22	13	14	-33	12	-46
Gazyva	61	9	62	-1	60	11	60	-3	61	4
Pulmozyme	19	3	16	-11	18	-2	18	-9	16	-16
CellCept	28	-9	21	-30	43	51	34	7	31	17
Madopar	26	2	23	-3	24	-1	23	-1	23	-9

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

[illegible]

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024
Ocrevus	141	27	146	23	164	37	187	16	151	23
Hemlibra	135	16	152	64	131	36	226	72	195	60
Vabysmo	47	281	47	180	47	63	71	101	98	130
Tecentriq	156	30	163	32	182	5	158	21	148	7
Perjeta	434	14	366	25	323	9	336	-9	281	-27
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	88	32	94	52	81	26	102	26	98	25
Phesgo	63	75	72	87	87	129	175	142	183	230
Kadcyla	153	27	137	20	150	25	149	21	181	33
Evrysdi	161	169	91	8	62	-9	95	56	127	-15
Alecensa	153	15	129	4	123	4	150	12	143	2
Polivy	45	72	42	42	41	70	64	80	80	94
MabThera/Rituxan	94	-12	89	-7	83	-11	79	-23	87	2
Herceptin	224	6	184	-6	175	-9	153	-29	132	-34
Activase/TNKase	18	25	13	-16	17	5	12	-9	11	-37
Avastin	156	-11	133	-14	126	-16	144	-3	120	-15
Gazyva	45	14	41	7	42	31	50	11	49	18
Pulmozyme	19	17	15	32	18	18	21	-10	17	7
CellCept	59	30	51	13	54	16	47	-4	51	-8
Madopar	83	18	55	-11	66	21	69	3	78	4

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

9. Roche Group consolidated income statement for the six months ended 30 June 2025

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	23,985	6,959	-	30,944
Other revenue	870	35	-	905
Cost of sales	(4,363)	(3,643)	-	(8,006)
Research and development	(5,638)	(1,038)	-	(6,676)
Selling, general and administration	(3,401)	(1,576)	(2,101)	(7,078)
Other operating income and expense	179	(20)	82	241
Operating profit	11,632	717	(2,019)	10,330
Financing costs				(693)
Other financial income (expense)				(49)
Profit before taxes				9,588
Income taxes				(1,756)
Net income				7,832
Attributable to				
- Roche shareholders				7,410
- Non-controlling interests				422
Earnings per share and non-voting equity security				
Basic (CHF)				9.31
Diluted (CHF)				9.23

10. Roche Group core results reconciliation – Half Year 2025

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	30,944	-	-	-	-	-	-	-	-	30,944
Other revenue	905	-	-	-	-	-	-	-	-	905
Cost of sales	(8,006)	153	187	104	-	-	-	-	-	(7,562)
Research and development	(6,676)	358	152	92	-	-	-	-	-	(6,074)
Selling, general and administration	(7,078)	561	9	-	-	-	-	-	-	(6,508)
Other operating income and expense	241	(49)	-	39	(10)	84	-	-	-	305
Operating profit	10,330	1,023	348	235	(10)	84	-	-	-	12,010
Financing costs	(693)	-	-	-	9	4	-	-	-	(680)
Other financial income (expense)	(49)	-	-	-	-	-	-	-	-	(49)
Profit before taxes	9,588	1,023	348	235	(1)	88	-	-	-	11,281
Income taxes	(1,756)	(198)	(59)	(39)	(5)	(14)	-	114	(5)	(1,962)
Net income	7,832	825	289	196	(6)	74	-	114	(5)	9,319
Attributable to										
- Roche shareholders	7,410	828	288	196	(6)	74	-	114	(5)	8,899
- Non-controlling interests	422	(3)	1	-	-	-	-	-	-	420
EPS - diluted (CHF)	9.23	1.04	0.36	0.24	(0.01)	0.09	-	0.14	(0.01)	11.08

11. Divisional core results reconciliation – Half Year 2025

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	23,985	-	-	-	-	-	-	23,985
Other revenue	870	-	-	-	-	-	-	870
Cost of sales	(4,363)	27	113	104	-	-	-	(4,119)
Research and development	(5,638)	215	150	92	-	-	-	(5,181)
Selling, general and administration	(3,401)	158	1	-	-	-	-	(3,242)
Other operating income and expense	179	(49)	-	-	(10)	89	-	209
Operating profit	11,632	351	264	196	(10)	89	-	12,522
Diagnostics								
Sales	6,959	-	-	-	-	-	-	6,959
Other revenue	35	-	-	-	-	-	-	35
Cost of sales	(3,643)	126	74	-	-	-	-	(3,443)
Research and development	(1,038)	143	2	-	-	-	-	(893)
Selling, general and administration	(1,576)	139	8	-	-	-	-	(1,429)
Other operating income and expense	(20)	-	-	39	-	2	-	21
Operating profit	717	408	84	39	-	2	-	1,250
Corporate								
Selling, general and administration	(2,101)	264	-	-	-	-	-	(1,837)
Other operating income and expense	82	-	-	-	-	(7)	-	75
Operating profit	(2,019)	264	-	-	-	(7)	-	(1,762)

12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2025	31 December 2024	31 December 2023
Non-current assets			
Property, plant and equipment	21,744	22,557	21,724
Right-of-use assets	1,130	1,183	1,215
Goodwill	7,565	7,876	9,390
Intangible assets	16,767	17,303	14,828
Deferred tax assets	8,440	8,569	6,882
Defined benefit plan assets	1,560	2,256	1,019
Other non-current assets	1,857	2,021	1,964
Total non-current assets	59,063	61,765	57,022
Current assets			
Inventories	7,597	7,606	7,749
Accounts receivable	11,918	11,297	11,021
Current income tax assets	441	415	344
Other current assets	3,720	3,401	3,130
Marketable securities	4,472	10,342	5,134
Cash and cash equivalents	7,554	6,975	5,376
Assets held for sale	-	-	692
Total current assets	35,702	40,036	33,446
Total assets	94,765	101,801	90,468
Non-current liabilities			
Long-term debt	(26,464)	(30,722)	(24,809)
Net deferred tax liabilities	(861)	(832)	(593)
Defined benefit plan liabilities	(4,028)	(4,381)	(4,379)
Provisions	(1,030)	(1,079)	(1,059)
Other non-current liabilities	(1,758)	(1,603)	(1,541)
Total non-current liabilities	(34,141)	(38,617)	(32,381)
Current liabilities			
Short-term debt	(6,567)	(3,932)	(4,400)
Current income tax liabilities	(2,811)	(2,923)	(2,257)
Provisions	(1,815)	(1,726)	(1,684)
Accounts payable	(4,512)	(4,894)	(4,325)
Other current liabilities	(11,875)	(13,548)	(12,150)
Liabilities directly associated with assets held for sale	-	-	(8)
Total current liabilities	(27,580)	(27,023)	(24,824)
Total liabilities	(61,721)	(65,640)	(57,205)
Total net assets	33,044	36,161	33,263
Equity			
Capital and reserves attributable to Roche shareholders	28,678	31,767	29,315
Equity attributable to non-controlling interests	4,366	4,394	3,948
Total equity	33,044	36,161	33,263

13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2025	HY 2024
Cash flows from operating activities		
Cash generated from operations	13,791	12,772
(Increase) decrease in net working capital	(3,470)	(2,100)
Payments made for defined benefit plans	(326)	(313)
Utilisation of provisions	(658)	(469)
Other operating cash flows	-	-
Cash flows from operating activities, before income taxes paid	9,337	9,890
Income taxes paid	(2,237)	(1,976)
Total cash flows from operating activities	7,100	7,914
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,680)	(1,724)
Purchase of intangible assets	(1,476)	(368)
Disposal of property, plant and equipment	73	19
Disposal of intangible assets	2	-
Disposal of products	-	353
Business combinations and asset acquisitions	(895)	(2,456)
Divestment of subsidiaries	6	-
Interest and dividends received	88	106
Sales of marketable securities	123	130
Purchases of marketable securities	(61)	(78)
Sales (purchases) of money market instruments and time accounts over three months, net	5,665	1,168
Other investing cash flows	(12)	(15)
Total cash flows from investing activities	1,833	(2,865)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	-	4,852
Redemption and repurchase of bonds and notes	(2,479)	(1,849)
Increase (decrease) in commercial paper	3,453	713
Increase (decrease) in other debt	292	40
Hedging and collateral arrangements	(156)	(108)
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(588)	(521)
Principal portion of lease liabilities paid	(199)	(172)
Dividends paid	(7,943)	(7,889)
Equity-settled equity compensation plans, net of transactions in own equity	(504)	(514)
Other financing cash flows	1	(1)
Total cash flows from financing activities	(8,123)	(5,449)
Net effect of currency translation on cash and cash equivalents	(231)	(152)
Increase (decrease) in cash and cash equivalents	579	(552)
Cash and cash equivalents at beginning of period	6,975	5,376
Cash and cash equivalents at end of period	7,554	4,824